Prevalence of, and effect of semaglutide on, features of non-alcoholic steatohepatitis in patients with obesity with and without type 2 diabetes: analysis of data from two randomised placebo-controlled trials using SomaSignal tests

被引：0
|
作者：
Schattenberg, Joern [1 ]
Gronbaek, Henning [2 ]
Kliers, Iris [3 ]
Ladelund, Steen [3 ]
Long, Michelle [3 ]
Nygard, Sune Boris [3 ]
Sanyal, Arun [4 ]
Davies, Melanie [5 ,6 ]
机构：
[1] Univ Med Ctr Mainz, Metab Liver Res Program, Mainz, Germany
[2] Aarhus Univ Hosp, Dept Gastroenterol & Hepatol, Aarhus, Denmark
[3] Novo Nordisk, Soborg, Denmark
[4] Virginia Commonwealth Univ, Sch Med, Div Gastroenterol Hepatol & Nutr, Richmond, VA USA
[5] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England
[6] NIHR Leicester Biomed Res Ctr, Leicester, Leics, England
来源：
JOURNAL OF HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI-469
引用
收藏
页码：S811 / S812
页数：2
相关论文
共 50 条
  • [1] Semaglutide in patients with non-alcoholic steatohepatitis: subgroup analysis of a randomised, placebo-controlled phase 2 trial
    Francque, Sven
    Kjaer, Mette
    Ladelund, Steen
    Okanoue, Takeshi
    Mateva, Lyudmila
    Shrestha, Ichhya
    Harrison, Stephen
    JOURNAL OF HEPATOLOGY, 2021, 75 : S609 - S610
  • [2] Treatment monitoring with the Agile 3+score in patients with non-alcoholic steatohepatitis: analysis of data from a randomised placebo-controlled trial of semaglutide
    Castera, Laurent
    Fournier-Poizat, Celine
    Foucquier, Julie
    Kjaer, Mette
    Krarup, Niels
    Miette, Veronique
    Nygard, Sune Boris
    Patel, Ahsan Shoeb
    Sandrin, Laurent
    Schattenberg, Joern
    JOURNAL OF HEPATOLOGY, 2023, 78 : S817 - S818
  • [3] SEMAGLUTIDE IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: SUBGROUP ANALYSIS OF A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2 TRIAL
    Francque, Sven M.
    Kjaer, Mette Skalshoi
    Ladelund, Steen
    Okanoue, Takeshi
    Mateva, Lyudmila
    Shrestha, Ichhya
    Harrison, Stephen A.
    HEPATOLOGY, 2021, 74 : 1123A - 1124A
  • [4] Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes
    Lembo, Erminia
    Russo, Maria Francesca
    Verrastro, Ornella
    Anello, Danila
    Angelini, Giulia
    Iaconelli, Amerigo
    Guidone, Caterina
    Stefanizzi, Gianluigi
    Ciccoritti, Luigi
    Greco, Francesco
    Sessa, Luca
    Riccardi, Laura
    Pompili, Maurizio
    Raffaelli, Marco
    Vecchio, Fabio Maria
    Bornstein, Stefan R.
    Mingrone, Geltrude
    Gastaldelli, Amalia
    Capristo, Esmeralda
    DIABETES & METABOLISM, 2022, 48 (05)
  • [5] Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
    Loomba, Rohit
    Abdelmalek, Manal F.
    Armstrong, Matthew J.
    Jara, Maximilian
    Kjaer, Mette Skalshoi
    Krarup, Niels
    Lawitz, Eric
    Ratziu, Vlad
    Sanyal, Arun J.
    Schattenberg, Jorn M.
    Newsome, Philip N.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (06): : 511 - 522
  • [6] Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
    Younossi, Zobair M.
    Ratziu, Vlad
    Loomba, Rohit
    Rinella, Mary
    Anstee, Quentin M.
    Goodman, Zachary
    Bedossa, Pierre
    Geier, Andreas
    Beckebaum, Susanne
    Newsome, Philip N.
    Sheridan, David
    Sheikh, Muhammad Y.
    Trotter, James
    Knapple, Whitfield
    Lawitz, Eric
    Abdelmalek, Manal F.
    Kowdley, Kris V.
    Montano-Loza, Aldo J.
    Boursier, Jerome
    Mathurin, Philippe
    Bugianesi, Elisabetta
    Mazzella, Giuseppe
    Olveira, Antonio
    Cortez-Pinto, Helena
    Graupera, Isabel
    Orr, David
    Gluud, Lise Lotte
    Dufour, Jean-Francois
    Shapiro, David
    Campagna, Jason
    Zaru, Luna
    MacConell, Leigh
    Shringarpure, Reshma
    Harrison, Stephen
    Sanyal, Arun J.
    LANCET, 2019, 394 (10215): : 2184 - 2196
  • [7] FGF-21 analogues for treatment of non-alcoholic steatohepatitis and fibrosis: a meta-analysis with fragility index of phase 2 randomised placebo-controlled trials
    Mantovani, Alessandro
    Tilg, Herbert
    Targher, Giovanni
    GUT, 2024, 73 (08) : 1400 - 1402
  • [8] A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
    Stephen A. Harrison
    Nadege Gunn
    Guy W. Neff
    Anita Kohli
    Liping Liu
    Abbey Flyer
    Lawrence Goldkind
    Adrian M. Di Bisceglie
    Nature Communications, 12
  • [9] A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
    Harrison, Stephen A.
    Gunn, Nadege
    Neff, Guy W.
    Kohli, Anita
    Liu, Liping
    Flyer, Abbey
    Goldkind, Lawrence
    Di Bisceglie, Adrian M.
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [10] Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
    Armstrong, Matthew James
    Gaunt, Piers
    Aithal, Guruprasad P.
    Barton, Darren
    Hull, Diana
    Parker, Richard
    Hazlehurst, Jonathan M.
    Guo, Kathy
    Abouda, George
    Aldersley, Mark A.
    Stocken, Deborah
    Gough, Stephen C.
    Tomlinson, Jeremy W.
    Brown, Rachel M.
    Huebscher, Stefan G.
    Newsome, Philip N.
    LANCET, 2016, 387 (10019): : 679 - 690
12345